• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO

    1/3/24 7:00:00 AM ET
    $CRNX
    $FATE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRNX alert in real time by email

    - Series A led by Frazier Life Sciences, 5AM Ventures and DCVC Bio, bringing total raised to date to $82.5 million

    - Paul Grayson joins as Chief Executive Officer, bringing additional expertise in business strategy, oncology, and G-protein coupled receptor biology

    - Radionetics expands board of directors with the appointment of Eric Shiozaki, Ph.D., Partner at DCVC Bio

    Radionetics Oncology, Inc., a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, announces the completion of a $52.5 million Series A financing. The round was led by Frazier Life Sciences, 5AM Ventures, and new investor, DCVC Bio, with participation from Crinetics Pharmaceuticals, and GordonMD Global Investments, bringing the total raised to date to $82.5 million. Radionetics plans to use the proceeds to advance its pipeline of potent, small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) for the treatment of a broad range of cancers.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240103467273/en/

    Paul Grayson, CEO at Radionetics Oncology (Photo: Business Wire)

    Paul Grayson, CEO at Radionetics Oncology (Photo: Business Wire)

    "Powered by a team with a unique expertise in radiopharmaceuticals, GPCR biology, and small molecule chemistry, Radionetics is well-positioned to be a leader in the development of first-in-class radiopharmaceuticals," said Eric Shiozaki, Ph.D., Partner at DCVC Bio and newly appointed Director of Radionetics Oncology. "We are excited to support Radionetics in their pursuit of developing novel and potentially life-changing radiopharmaceuticals for cancer patients."

    Concurrent with the financing, Radionetics Oncology also announced the appointment of Paul Grayson as the company's Chief Executive Officer. Paul brings a wealth of knowledge across a broad range of technologies from his time leading cutting-edge biotech companies over the past 25 years. He was most recently the President and CEO of Tentarix Biotherapeutics, an oncology company focused on multi-functional biologics. His previous experiences additionally include founding roles at Fate Therapeutics (NASDAQ:FATE), BirdRock Bio (acquired by Skye Biosciences), Senomyx (acquired by Firmenich), and Aurora Biosciences (acquired by Vertex Pharmaceuticals).

    "I'm thrilled to join Radionetics at such an exciting time in the evolution of the company and radiopharmaceutical therapeutics," said Paul Grayson, President and Chief Executive Officer. "The spatial biology and pharmacology of GPCRs makes them ideal for small molecule radiopharmaceutical development, opening a new chapter for the field."

    About Radionetics Oncology

    Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications and is poised to capitalize on the increasing demand for novel radiotherapeutics. Radionetics Oncology spun out of Crinetics Pharmaceuticals (NASDAQ:CRNX) and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Global Investments. Radionetics is advancing a pipeline of novel small molecule radioligands targeting G-protein coupled receptors for the treatment of a broad range of cancers, including adrenocortical carcinoma, breast cancer, lung cancer, among others.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240103467273/en/

    Get the next $CRNX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CRNX
    $FATE

    CompanyDatePrice TargetRatingAnalyst
    Crinetics Pharmaceuticals Inc.
    $CRNX
    3/25/2025$60.00Buy
    Stifel
    Crinetics Pharmaceuticals Inc.
    $CRNX
    2/11/2025Buy
    TD Cowen
    Crinetics Pharmaceuticals Inc.
    $CRNX
    2/4/2025Peer Perform
    Wolfe Research
    Crinetics Pharmaceuticals Inc.
    $CRNX
    1/22/2025$55.00Hold → Buy
    Jefferies
    Fate Therapeutics Inc.
    $FATE
    11/18/2024Underperform → Neutral
    BofA Securities
    Fate Therapeutics Inc.
    $FATE
    6/17/2024$4.00 → $6.00Neutral → Overweight
    Piper Sandler
    Crinetics Pharmaceuticals Inc.
    $CRNX
    3/6/2024$68.00Buy
    Citigroup
    Crinetics Pharmaceuticals Inc.
    $CRNX
    1/16/2024$50.00Overweight
    Morgan Stanley
    More analyst ratings

    $CRNX
    $FATE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Redmile Group, Llc sold $573,943 worth of shares (341,633 units at $1.68), bought $668,580 worth of shares (397,964 units at $1.68), disposed of $1,822,692 worth of shares (1,084,936 units at $1.68) and acquired $1,822,692 worth of shares (1,084,936 units at $1.68) (SEC Form 4)

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      12/26/24 9:00:15 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Redmile Group, Llc disposed of $6,157,976 worth of shares (1,655,370 units at $3.72), acquired $6,157,976 worth of shares (1,655,370 units at $3.72) and bought $166,024 worth of shares (44,630 units at $3.72) (SEC Form 4)

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      12/28/23 9:30:16 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRNX
    $FATE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on July 2, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 30,000 shares of the Company's common stock at an exercise price per share of $1.12, which was the closing price per share of the Company's common stock as reported by NASDAQ on July 2, 2025, the options grant date, and (ii) restricted stock units

      7/3/25 1:05:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

      SAN DIEGO, June 16, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that it will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025, from 9:00 AM to 12:00 PM ET. The event will provide an update including data on Crinetics' early-stage pipeline assets, next steps, and portfolio strategy to drive long-term value. Key topics will include: NETs and beyond – NDC platform with CRN09682Graves' disease and thyroid eye disease (TED) - TSH antagonistAutosomal polycystic kidney disease (ADPKD) - SST3 agonist A live question-and-answer session will follow the formal presentations. To register, click here. About Crinetics Pharmaceut

      6/16/25 8:00:00 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

      All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up continues in drug-free Definition of Remission in SLE (DORIS) First extrarenal SLE patient on maintenance therapy treated with FT819 in the absence of conditioning achieves Low Lupus Disease Activity State (LLDAS) at 3-month follow-up and maintained at 6 months Cumulative clinical experience in nearly 60 patients treated with off-the-shelf program across autoimmunity and oncology continues to support therapeutic differentiation with favorable safety profile and short duration of hospitalizati

      6/11/25 9:00:00 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRNX
    $FATE
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Fate Therapeutics Inc.

      SCHEDULE 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)

      7/3/25 4:01:26 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

      6/30/25 4:26:17 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

      6/26/25 4:16:14 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRNX
    $FATE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Crinetics Pharmaceuticals with a new price target

      Stifel initiated coverage of Crinetics Pharmaceuticals with a rating of Buy and set a new price target of $60.00

      3/25/25 8:26:55 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Crinetics Pharmaceuticals

      TD Cowen initiated coverage of Crinetics Pharmaceuticals with a rating of Buy

      2/11/25 7:03:38 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Crinetics Pharmaceuticals

      Wolfe Research initiated coverage of Crinetics Pharmaceuticals with a rating of Peer Perform

      2/4/25 7:01:38 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRNX
    $FATE
    Leadership Updates

    Live Leadership Updates

    See more
    • Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

      SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne

      5/30/25 4:30:14 PM ET
      $FATE
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

      SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Tobin "Toby" Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations. "I am excited to welcome Toby to our senior leadership team during this transformational stage of our evolution into a global pharmaceutical company," said Scott Struthers, Ph.D., founder and chief executive officer of Crineti

      2/24/25 8:30:00 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

      SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company's commercial strategy and operations for the potential launch of paltusotine, the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist for adults living with acromegaly and will lead pre-commercialization activities for the company's deep, innovative pipeline of candidates. "Isabel is a highly accomplished leader with broad commercial expertise ranging from launching therapies to leading early-stage commercial strategy," said Scott Struthers, Ph.D

      12/16/24 8:00:00 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRNX
    $FATE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

      SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

      11/14/24 7:55:29 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Fate Therapeutics Inc.

      SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

      11/14/24 7:50:18 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

      SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

      11/14/24 5:46:54 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRNX
    $FATE
    Financials

    Live finance-specific insights

    See more
    • Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date   CALM-CAH Phase 3 Study of Atumelnant for the Treatment of Adults with Congenital Adrenal Hyperplasia to Initiate with Uncompromising Primary Endpoint to Normalize Androstenedione Levels with Physiologic Glucocorticoid Replacement R&D Day Scheduled for June 26 to Share Early-Stage Pipeline Strategy and Data $1.3B in Cash, Cash Equivalents, and Investment Securities as of March 31, 2025 Anticipated to Provide Runway into 2029 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Crin

      5/8/25 4:05:00 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

      SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 8 @ 4:30 p.m. ET Domestic:1-833-470-1428International:1-404-975-4839Conference ID:CRNXQ1 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended

      4/11/25 8:00:00 AM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

      SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 27 @ 4:30 p.m. ET Domestic:         1-800-267-6316International:    1-203-518-9783Conference ID:  CRNXQ4 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely

      2/6/25 4:35:20 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRNX
    $FATE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Redco Ii Master Fund, L.P. claimed ownership of 8,977,624 shares (SEC Form 3)

      3 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      7/3/25 4:03:21 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Betz Stephen F. exercised 88,170 shares at a strike of $3.30 and sold $3,141,877 worth of shares (97,483 units at $32.23), decreasing direct ownership by 9% to 99,713 units (SEC Form 4)

      4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

      6/16/25 4:48:09 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Deardorf Caren was granted 6,900 shares, increasing direct ownership by 73% to 16,300 units (SEC Form 4)

      4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

      6/13/25 4:30:20 PM ET
      $CRNX
      Biotechnology: Pharmaceutical Preparations
      Health Care